The Stabilization of Plaques UsingDarapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI) 52 trial showedthat cystatin C improved the prediction of cardiovascular disease/heart failure(CVD/HF) hospitalization when added to a non-eGFR adjusted model in ACS [15].Inês Almeida et al. [19] found that eGFRcys, calculated usingthe CKD-EPI 2012 equation, offers a novel and superior method for assessingmortality risk in patients admitted for ACS. This evidence concerns the gene CST3 and cardiovascular disorder.